Immucell (ICCC) Current Deferred Revenue (2011 - 2018)

Immucell (ICCC) has reported Current Deferred Revenue for 8 consecutive years, with $24100.0 the latest figure, recorded in Q3 2018.

• For the quarter ending Q3 2018, Current Deferred Revenue changed N/A year-over-year to $24100.0; the trailing twelve-month figure through Sep 2018 stood at $24100.0 (changed N/A YoY), and the FY2017 full-year result was $24100.0, down 28.82% from the prior year.
• Current Deferred Revenue was little changed at $24100.0 in Q3 2018 per ICCC's latest filing, from $24100.0 in the prior quarter.
• Across five years, Current Deferred Revenue topped out at $33856.0 in Q3 2016 and bottomed at $6690.0 in Q3 2014.
• Historically, Current Deferred Revenue has averaged $20464.7 across 5 years, with a median of $24100.0 in 2017.
• The widest YoY moves for Current Deferred Revenue: up 28.82% in 2017, down 28.82% in 2017.
• Over 5 years, Current Deferred Revenue stood at $6690.0 in 2014, then changed by 0.0% to $6690.0 in 2015, then surged by 406.07% to $33856.0 in 2016, then slipped by 28.82% to $24100.0 in 2017, then changed by 0.0% to $24100.0 in 2018.
• According to Business Quant data, Current Deferred Revenue over the past three periods registered $24100.0, $24100.0, and $24100.0 for Q3 2018, Q2 2018, and Q1 2018 respectively.